Floatz logo

Sodium Oligomannate

Treatment

First Affiliated Hospital Xi'an Jiaotong UniversityPhase 4 / ApprovedActive
B
62/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
50/ 100
Competitive Position
81/ 100

Competitive context

8 Active assets in the Treatment cohort.

Asset / SponsorPhaseRating
CIS-DIAMMINEDICHLOROPLATINUM II
Peking Union Medical College Hospital
Phase 2B
Capecitabine
Henan Cancer Hospital
Phase 2CCC
INSULIN SUSP ISOPHANE RECOMBINANT HUMAN
University Hospital, Strasbourg, France
Phase 2CCC
Vinorelbine
Henan Cancer Hospital
Phase 2CCC
Letrozole
University Hospital, Strasbourg, France
Phase 2CCC

View all 10 →

Same molecule, other indications

Sodium Oligomannate is also rated in:

EfficacyDormant
B
Indicative ·
62 / 100
View asset →
SafetyDormant
B
Indicative ·
62 / 100
View asset →
Alzheimer diseaseDormant
B
Indicative ·
56 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →